Compare Neurocrine Biosciences Inc (NBIX) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Ralph Lauren Corp — how do they compare? Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B), while Ralph Lauren Corp trades at $397.75 (market cap $24.24B). The key difference: Ralph Lauren Corp is the larger of the two by market cap, and Ralph Lauren Corp pays a 0.92% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | RL | |
|---|---|---|
Market Cap | $16.76B | $24.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $414.25 |
52-Week Low | $123.10 | $285.35 |
Enterprise Value | $16.78B | $25.31B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Ralph Lauren (RL) trades at $395.53, down 0.08% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q1 2027 EPS of $4.59 exceeding expectations of $4.32, driven by robust demand and margin expansion. Revenue growth accelerated to 13% in constant currency, and the company updated its fiscal 2027 outlook upward. Key support lies at $388, with resistance at $402.
The investment outlook is positive, supported by earnings momentum, brand strength, and a 66% analyst buy rating. Risks include high valuation multiples, such as a P/E of 24.92, and sensitivity to consumer spending trends. The consensus price target of $456.50 implies 15% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
